[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337585-105":59,"doc-detail-337585-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-molecular-approach-to-triple-negative-breast-cancer-targeting-the-notch-signaling-pathway","A molecular approach to triple-negative breast cancer - targeting the Notch signaling pathway","","Triple-negative breast cancer (TNBC) is a highly aggressive subtype lacking estrogen receptor, progesterone receptor, and HER2 expression, which makes cells resistant to conventional treatments and associated with poor clinical outcomes. Dysregulation of the Notch receptor signaling pathway has been linked to TNBC development and progression. A comprehensive literature review identifies upstream and downstream Notch components as potential therapeutic targets, while emphasizing the need for further studies on toxicity and drug delivery to support translation into effective patient treatments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-molecular-approach-to-triple-negative-breast-cancer-targeting-the-notch-signaling-pathway/337585/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-molecular-approach-to-triple-negative-breast-cancer-targeting-the-notch-signaling-pathway/337585.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes triple-negative breast cancer particularly difficult to treat?","Question",{"text":112,"@type":113},"TNBC is defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, producing resistance to conventional therapies and leading to poor outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why focus on the Notch signaling pathway in TNBC?",{"text":117,"@type":113},"Research indicates that Notch signaling contributes to TNBC’s aggressive clinical course and metastatic tendency, supporting its role in tumorigenesis and drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What potential therapeutic targets does the review discuss?",{"text":121,"@type":113},"The review analyzes upstream and downstream Notch pathway components, including Notch ligands and other molecules involved in TNBC growth, as candidate targets still in early development.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337585,1790484067,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Official Publication of the Instituto Israelita de Ensino e Pesquisa Albert Einstein  \ne-ISSN: 2317-6385  \nHow to cite this article:  \nPardo I, Fagundes PB, Oliveira RS, Campregher PV. A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway. einstein (São Paulo) . 2024;22:eRW0552 .  \nAssociate Editor:  \nKenneth Gollob  \nHospital Israelita Albert Einstein, São Paulo, SP, Brazil  \nORCID: [https://orcid.org/0000-0003-4184-3867](https://orcid.org/0000-0003-4184-3867)  \n[Corresponding author:](Corresponding author:)  \nIsabele Pardo  \nRua Comendador Elias Jafet, 755-Morumbi Zip code: 05653-000-São Paulo, SP, Brazil  \nPhone: (55 11) 99441-1100  \nE-mail: [pardoisabele@gmail.com](pardoisabele@gmail.com)  \nReceived on:  \nApr 17, 2023  \nAccepted on:  \nSep 19, 2023  \nCopyright the authors  \nThis content is licensed  \nunder a Creative Commons Attribution 4.0 International License.  \nREVIEW  \nA molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway  \nIsabele Pardo1, Pedro Brecheret Fagundes1, Rafael Santana de Oliveira1, Paulo Vidal Campregher1 1 Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.  \nDOI: 10.31744/einstein_journal/2024RW0552  \n❚ ABSTRACT  \nIntroduction: Triple-negative breast cancer is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This phenotype renders triple-negative breast cancer cells refractory to conventional therapies, resulting in poor clinical outcomes and an urgent need for novel therapeutic approaches. Recent studies have implicated dysregulation of the Notch receptor signaling pathway in the development and progression of triple-negative breast cancer. Objective: This study aimed to conduct a comprehensive literature review to identify potential therapeutic targets of the Notch pathway. Our analysis focused on the upstream and downstream components of this pathway to identify potential therapeutic targets. Results: Modulating the Notch signaling pathway may represent a promising therapeutic strategy to treat triple-negative breast cancer. Several potential therapeutic targets within this pathway are in the early stages of development, including upstream (such as Notch ligands) and downstream (including specific molecules involved in triple-negative breast cancer growth) . These targets represent potential avenues for therapeutic intervention in triple-negative breast cancer. Comments: Additional research specifically addressing issues related to toxicity and improving drug delivery methods is critical for the successful translation of these potential therapeutic targets into effective treatments for patients with triple-negative breast cancer.  \nKeywords: Receptors, Notch1; Triple-negative breast neoplasms; Molecular targeted therapy; Signal transduction; Cell proliferation; MicroRNAs  \n❚ INTRODUCTION  \nBreast cancer is the most common type of cancer in women worldwide and accounted for approximately 15.5% of all cancer deaths in females in 2020.(1) Triple-negative breast cancer (TNBC) constitutes 15-20% of all breast malignancies and is associated with a poor prognosis.(2) It is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) gene expression.(3-5) It exhibits molecular heterogeneity(6,7) with six distinct gene expression profile subtypes: basallike 1 (BL1), basal-like 2 (BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) .(7) Both BL-TNBC strains exhibit deficiencies in gene expression associated with DNA repair. Conversely, subtypes M and MSL are characterized by significant expression of genes essential for epithelial-mesenchymal transition (EMT) . Additionally, the LAR subtype expresses genes related to certain intr","cbCaiuSMHIiBYKh7","https://ap.wps.com/l/cbCaiuSMHIiBYKh7","pdf",282756,"English","# Abstract\n# Introduction\n## Notch inhibition pathways\n## Simplified Notch pathway","[{\"question\":\"What makes triple-negative breast cancer particularly difficult to treat?\",\"answer\":\"TNBC is defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, producing resistance to conventional therapies and leading to poor outcomes.\"},{\"question\":\"Why focus on the Notch signaling pathway in TNBC?\",\"answer\":\"Research indicates that Notch signaling contributes to TNBC’s aggressive clinical course and metastatic tendency, supporting its role in tumorigenesis and drug resistance.\"},{\"question\":\"What potential therapeutic targets does the review discuss?\",\"answer\":\"The review analyzes upstream and downstream Notch pathway components, including Notch ligands and other molecules involved in TNBC growth, as candidate targets still in early development.\"}]","A molecular approach to triple-negative breast cancer - targeting the Notch signaling pathway | PDF",1790019685,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e89c74aba7d7ae7783603b5778f1606.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b660bdf6b2f02ba59baa9ec5aa2c603.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b184e5da951a4c0f7dd2f0036dffcb9e.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/666f0112f4c40f19adb310e06964a633.webp",980,1306]